PH
Phio Pharmaceuticals Corp.
PHIO · NASDAQ
$1.01 +1.00% (+$0.01)
1M -7.34%
Market Cap $11.7M
P/E Ratio -
Div. Yield -
ROE 87.41%
Bulios Fair Price
$1.24
22.8% upside
Current Price
$1.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PHIO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.93x
PEG N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 22.95%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 90.19%
ROIC 100.51%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 15.87x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
37 /100
Moderate Profitable years 0
Beta 0.80x
EPS volatility 80.39%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PHIO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert L. Bitterman
Employees
6
Headquarters
King of Prussia
Upcoming events
12 NOV
Earnings
Upcoming earnings report